X-Ray Inspection More Than Just Contamination Detection

June 3, 2019

This white paper looks at the potential of x-ray inspection to solve a wide range of product safety and quality control issues typically found within food and pharmaceutical manufacturing. It explores how x-ray inspection can detect faulty products before they leave the factory, avoiding product recalls and customer disappointment. It describes how in a single pass – and at high line speeds – x-ray systems can perform several inspection tasks simultaneously.

Spotlight

DAVA Oncology

Optimize the recruitment and retention of patients in cancer clinical trials through the use of physician-focused approaches. DAVA has a proven track record having completed more than 45 Phase I to III trials and over the past six years with an average accrual enhancement rate of 30-40%.

OTHER WHITEPAPERS
news image

Association for Accessible Medicines Drug Shortages

whitePaper | June 22, 2023

Generic medicines are the backbone of the U.S. prescription drug market, supplying more than 9 out of every 10 prescriptions. And the availability of generic medicines overall is remarkably stable even during challenges such as the COVID-19 pandemic.

Read More
news image

A Futuristic Approach to Message Testing for Pharma Companies

whitePaper | March 10, 2023

In the last decade, the pharma industry has gone through significant changes in how it messages to physicians, patients and payers. The processes and tools that pharma brands use to DEVELOP and DELIVER messages have been disrupted by new technologies.

Read More
news image

Understanding the true cost of transparency reporting

whitePaper | December 14, 2022

When the regulatory hammer came down on pharmaceutical and life sciences (PLS) companies in the 2010s, it introduced new complexities for these businesses.

Read More
news image

Vendor Partnering in a Bioprocess Manufacturing and Supply Chain Ecosystem

whitePaper | October 14, 2022

Supply constancy, cost, sterility – even a subset of the factors that impact materials selection can be daunting for biopharmaceutical companies embarking on a new drug development project.

Read More
news image

Pharma R&D Annual Review

whitePaper | March 15, 2022

Successes in 2021 – New active substance drug launches

Read More
news image

Transforming Patient Journey in Clinical Trials

whitePaper | April 7, 2022

Year after year, the Life Sciences industry expands at a breakneck pace, with pharmaceutical development leading the way.

Read More

Spotlight

DAVA Oncology

Optimize the recruitment and retention of patients in cancer clinical trials through the use of physician-focused approaches. DAVA has a proven track record having completed more than 45 Phase I to III trials and over the past six years with an average accrual enhancement rate of 30-40%.

Events